Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations

Clinical Biochemistry

Volumn 41, Issue 7-8, 2008, Pages 603-606

  Paz, Eduardo ^a   Bouzas, Lorena ^b   Hermida, Jesús ^b   Brenlla, Julio ^c   Tutor, J Carlos ^b  

^a Hôpital Psychiatrique de Conxo   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

Author keywords

Clozapine; Norclozapine; Predicted clozapine concentrations; Therapeutic drug monitoring

Indexed keywords

CLOZAPINE; NORCLOZAPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; PREDICTION; PRIORITY JOURNAL; QUALITY CONTROL; SCHIZOPHRENIA; STEADY STATE;

ADULT; AGED; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SMOKING;

EID: 41949135574     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.01.020     Document Type: Article

References (13)

1. Bell R., McLaren A., Galanos J., and Copolov D. The clinical use of plasma clozapine. Australian New Zealand J Psychiatry 32 (1998) 567-574
2. Spina E., Avenoso A., Facciola G., et al. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 148 (2000) 83-89
3. Ulrich S., Baurmann B., Wolf R., et al. Therapeutic drug monitoring of clozapine and relapse-a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 41 (2003) 3-13
4. Kaladjian A., Bery B., Deturmeny E., and Bruguerolle B. Clozapine monitoring: plasma or serum levels?. Ther Drug Monit 21 (1999) 327-329
5. Hermida J., Paz E., and Tutor J.C. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients. Ther Drug Monit 30 (2008) 41-45
6. Oyewumi L.K., Freeman D.J., and Vollick D. Can low-dose clozapine pharmacokinetics predict steady-state plasma concentrations. Ther Drug Monit 17 (1995) 137-141
7. Perry P.J., Bever K.A., Arndt S., and Combs M.D. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 44 (1998) 733-738
8. Rostami-Hodjegan A., Amin A.M., Spencer E.P., Lennard M.S., Tucker G.T., and Flanagan R.J. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24 (2004) 70-78
9. Shah V.P., Midha K.K., Dighe S., et al. Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Eur J Drug Metab Pharmacokinet 16 (1991) 249-255
10. Guitton C.G., Kinowski J.M., Abbar M., Chabrand P., and Bressolle F. Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia. J Clin Pharmacol 39 (1999) 721-728
11. De León J. Atypical antipsychotic dosing: the effect of co-medication with anticonvulsants. Psychiatric Serv 55 (2004) 125-128
12. Ng C.H., Chong S.A., Lambert T., et al. An inter-ethnic comparison study of clozapine dosage, clinical response and plasma levels. Int J Clin Psychopharmacol 20 (2005) 163-168
13. Gornall A.G. Basic concepts in laboratory investigation. In: Gornall A.G. (Ed). Applied biochemistry of clinical disorders. 2nd Edition (1986), JB Lippincott, Philadelphia 3-13